Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
Nurix Therapeutics reports 2022 executive compensation
By ExecPay News
Published: March 24, 2023
Nurix Therapeutics reported fiscal year 2022 executive compensation information on March 24, 2023.
In 2022, three executives at Nurix Therapeutics received on average a compensation package of $5.8M, a 67% increase compared to previous year.
Average pay of disclosed executives at Nurix Therapeutics
Arthur T. Sands, Chief Executive Officer, received $9.4M in total, which increased by 97% compared to 2021. 90% of Sands' compensation, or $8.5M, was in option awards. Sands also received $293K in non-equity incentive plan, $572K in salary, as well as $46K in other compensation.
Hans van Houte, Chief Financial Officer, received a compensation package of $4.3M, which increased by 160% compared to previous year. 64% of the compensation package, or $2.8M, was in option awards.
Gwenn Hansen, Chief Scientific Officer, earned $3.8M in 2022, a 66% increase compared to previous year.
Nurix Therapeutics' fiscal year ends on November 30.
Related executives
You may also like
Source: SEC filing on March 24, 2023.